Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy.
Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Clin Microbiol Infect. 2022 Aug;28(8):1057-1065. doi: 10.1016/j.cmi.2022.02.039. Epub 2022 Mar 12.
A significant increased risk of complications and mortality in immunocompromised patients affected by COVID-19 has been described. However, the impact of COVID-19 in solid organ transplant (SOT) recipients is an issue still under debate, due to conflicting evidence that has emerged from different observational studies.
We performed a systematic review with a meta-analysis to assess the clinical outcome in SOT recipients with COVID-19 compared with the general population.
PubMed-MEDLINE and Scopus were independently searched until 13 October 2021.
Prospective or retrospective observational studies comparing clinical outcome in SOT recipients versus general populations affected by COVID-19 were included. The primary endpoint was 30-day mortality.
Participants were patients with confirmed COVID-19.
Interventions reviewed were SOTs.
The quality of the included studies was independently assessed with the Risk of Bias in Non-randomized Studies of Interventions tool for observational studies. The meta-analysis was performed by pooling ORs retrieved from studies providing adjustment for confounders using a random-effects model with the inverse variance method. Multiple subgroups and sensitivity analyses were conducted to investigate the source of heterogeneity.
A total of 3501 articles were screened, and 31 observational studies (N = 590 375; 5759 SOT recipients vs. 584 616 general population) were included in the meta-analyses. No difference in 30-day mortality rate was found in the primary analysis, including studies providing adjustment for confounders (N = 17; 3752 SOT recipients vs. 159 745 general population; OR: 1.13; 95% CI, 0.94-1.35; I = 33.9%). No evidence of publication bias was reported. A higher risk of intensive care unit admission (OR: 1.56; 95% CI, 1.03-2.63) and occurrence of acute kidney injury (OR: 2.50; 95% CI, 1.81-3.45) was found in SOT recipients.
No increased risk in mortality was found in SOT recipients affected by COVID-19 compared with the general population when adjusted for demographic and clinical features and COVID-19 severity.
已描述免疫功能低下的 COVID-19 患者发生并发症和死亡的风险显著增加。然而,由于来自不同观察性研究的相互矛盾的证据,COVID-19 在实体器官移植(SOT)受者中的影响仍然存在争议。
我们进行了一项系统评价和荟萃分析,以评估 COVID-19 患者与一般人群相比的临床结局。
PubMed-MEDLINE 和 Scopus 分别独立检索至 2021 年 10 月 13 日。
前瞻性或回顾性观察性研究,比较 SOT 受者与 COVID-19 一般人群的临床结局。主要终点为 30 天死亡率。
参与者为确诊 COVID-19 患者。
研究中评估的干预措施为 SOT。
使用针对观察性研究的非随机干预措施风险偏倚评估工具,独立评估纳入研究的质量。通过汇总提供混杂因素调整的研究中的 OR,使用随机效应模型和倒数方差法进行荟萃分析。进行了多个亚组和敏感性分析,以调查异质性的来源。
共筛选出 3501 篇文章,纳入 31 项观察性研究(N=590375;5759 例 SOT 受者与 584616 例一般人群)进行荟萃分析。在主要分析中,未发现 30 天死亡率存在差异,包括提供混杂因素调整的研究(N=17;3752 例 SOT 受者与 159745 例一般人群;OR:1.13;95%CI,0.94-1.35;I²=33.9%)。未报告发表偏倚的证据。SOT 受者入住重症监护病房(OR:1.56;95%CI,1.03-2.63)和发生急性肾损伤(OR:2.50;95%CI,1.81-3.45)的风险更高。
在调整人口统计学和临床特征以及 COVID-19 严重程度后,COVID-19 患者的 SOT 受者与一般人群相比,死亡率无增加风险。